Related Experiment Video
Updated: Jun 13, 2026

14:27
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
Published on: June 26, 2013
16.0K
Machine Learning and Multiparametric Brain MRI to Differentiate Hereditary Diffuse Leukodystrophy with Spheroids from
Gabriel Mangeat1, Russell Ouellette2,3, Maxime Wabartha1
1NeuroPoly Lab, Institute of Biomedical Engineering, Polytechnique Montreal, Montreal, Quebec, Canada.
Summary
A new machine learning method using quantitative MRI can accurately distinguish between Hereditary diffuse leukoencephalopathy with spheroids (HDLS) and multiple sclerosis (MS). This aids in the correct diagnosis of rare HDLS, improving patient outcomes.
Area of Science:
- Neuroimaging
- Machine Learning
- Differential Diagnosis
Background:
- Hereditary diffuse leukoencephalopathy with spheroids (HDLS) and multiple sclerosis (MS) are challenging to differentiate due to overlapping symptoms.
- Misdiagnosis of HDLS as MS can lead to inappropriate treatment and management.
Purpose of the Study:
- To develop and validate a machine learning method for robust classification of HDLS versus MS using quantitative MRI.
- To improve the diagnostic accuracy for rare neurological disorders like HDLS.
Main Methods:
- A quantitative brain MRI protocol (synthetic MRI) was applied to 4 HDLS and 14 MS patients at 3 Tesla.
- Machine learning models were trained using quantitative MRI features.
- Repeatability analysis was performed on healthy controls across different field strengths (3T and 1.5T).
Main Results:
- The machine learning model achieved 100% correct classification in cross-validation using 5-11 quantitative MRI features.
- High true positive rates were observed even with added measurement noise (97.2% for HDLS, 99.6% for MS).
- Predicting features showed high measurement confidence (1.7% at 3T, 2.3% at 1.5T).
Conclusions:
- Quantitative MRI combined with machine learning shows promise for computer-assisted differential diagnosis of HDLS and MS.
- This approach can aid clinicians in identifying patients with a high probability of HDLS, guiding further genetic testing.

